CEFODIZIME (THR-221) IN RESPIRATORY TRACT INFECTIONS

• Published in: CHEMOTHERAPY Vol. 36; no. Supplement5; pp. 308 - 313
• Main Authors: MAIYA, NORIMI, KOBAYASHI, HITOSHI, SHIBA, AKIKO, ITOH, TAKASHI, TAMURA, MASAO, MORIYA, KATSURA, ITAKURA, KOTARO, GOMI, KAZUTOSHI, KURAMITSU, HIROSHI, TANIFUJI, KAZUO, SATO, NOBUHISA, MIYA, KAZUMICHI
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1988
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.36.Supplement5_308

We studied the clinical efficacy and safety of cefodizime (THR-221), a new cephalosporin derivative developed by Hoechst and Roussel CO., in 26 patients with respiratory tract infection. Twenty-three had bacterial pneumonia, two had secondary infection of chronic pulmonary emphysema and one mycoplasma pneumonia. The results were as follows: 1. Clinical response was excellent in 4 cases, good in 18 and fair in 3. The overall efficacy rate was 84.6%. 2. Organisms isolated were H.infltsenzae (3 strains), K. pneumoniae (1 strain) and E. cloacae (1 strain). All strains were eradicated after treatment with cefodizime. 3. No adverse reactions were observed. Laboratory studies revealed elevation of liver enzyme levels in 3 patients and leukopenia in 2. From the above results, we consider cefodizime to be a useful antibiotic for the treatment of bacterial respiratory tract infections.